Product News
Filter News
Found 230,836 articles
-
FDA grants Breakthrough Therapy designation for lecanemab in Alzheimer's disease
6/24/2021
BioArctic AB's today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease.
-
China's first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876)
6/24/2021
Fosun Kite Biotechnology announced its autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel has been approved by China National Medical Products Administration for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
-
Hyloris Successfully Renegotiates License Agreements for Lead Products with the Alter Pharma Group
6/24/2021
Hyloris Pharmaceuticals SA, a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, announces that it has successfully renegotiated and unwound its earlier license agreements with the Alter Pharma Group.
-
Concerns over vaccination links to heart inflammation are valid, a U.S. Centers for Disease Control and Prevention advisory committee announced this afternoon.
-
The drug was approved on June 7 under the agency’s accelerated approval pathway, despite the agency’s Peripheral and Central Nervous System Drugs Advisory Committee voting against the drug in November 2020 and having been assured at that time the agency was not considering an accelerated approval.
-
The medical regulator's green light is a milestone in the global fight against specific types of late-stage blood cancer, as CAR T-cell therapy has been found to be effective against them.
-
Crisis has a way of opening doors of opportunity for fraud around the globe. The COVID-19 pandemic has brought not only a fresh slew of financial schemes, but pharmaceutical fraud as well.
-
Money on the Move: June 16 – 22
6/23/2021
Life sciences advances continue to be an exciting opportunity for investors. Here's a glance at the companies attracting fresh funding the past week. -
uniQure has acquired Corlieve with upfront cash of approx. $55 million and will center on the latter's lead program, AMT-260, an advanced treatment for TLE.
-
A new research paper published by Alzheon suggests the inhibition of amyloid toxicity is the only clinically validated strategy for slowing Alzheimer’s disease progression.
-
Cocrystal Pharma Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter
6/23/2021
Cocrystal Pharma, Inc. announces the completion of IND-enabling studies with its potent, broad-spectrum PB2 inhibitor CC-42344 for the treatment of seasonal and pandemic influenza A and plans to initiate Phase 1.
-
Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints
6/23/2021
Entera Bio Ltd. announced the final 6-month bone mineral density (BMD) results from the completed Phase 2 clinical trial of EB613 for the treatment of osteoporosis.
-
Cipher Pharmaceuticals Reports Voting Results From Annual Meeting of Shareholders
6/23/2021
Cipher Pharmaceuticals Inc. today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today.
-
Rafael Holdings and Rafael Pharmaceuticals Management Presented at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021
6/23/2021
Rafael Holdings, Inc., (NYSE: RFL) and Rafael Pharmaceuticals today announced that Ameet Mallik , CEO of Rafael Holdings, Inc., Sanjeev Luther , President & CEO of Rafael Pharmaceuticals, and Tim Pardee , Co-Chief Medical Officer of Rafael Pharmaceuticals, presented at the Raymond James 2021 Human Health Innovation Conference.
-
Second Sight Medical Products Announces Pricing of Public Offering
6/23/2021
Second Sight Medical Products, Inc. (NASDAQ: EYES) (“Second Sight” or the “Company”), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share,
-
GT Biopharma Announces Interim GTB-3550 Trike™ Monotherapy Clinical Trial Results At 2021 Raymond James Human Health Innovation Conference
6/23/2021
GT Biopharma, Inc.announced Jeffrey S. Miller, M.D., Deputy Director of the Masonic Cancer Center and Consulting Chief Scientific Officer, provided an update concerning GTB-3550 TriKE.
-
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara’s Biosimulation Software for Evaluating Regulatory SubmissionsThe PMDA enters 8th consecutive year of using Certara’s biosimulation software
6/23/2021
Certara today announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has renewed its licenses of Certara’s Simcyp™ and Phoenix™ biosimulation software.
-
Nasus Pharma Announces Positive Results from a Pilot Clinical Study of FMXIN002 Intranasal Powder Epinephrine Spray in Patients with Seasonal Allergic Rhinitis
6/23/2021
Nasus Pharma Ltd announced positive results from a pilot trial of intranasal powder-based Epinephrine.
-
Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus
6/23/2021
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist has demonstrated the potential to provide extended efficacy.
-
Seal Rock Therapeutics Announces Initiation of Phase 1 Clinical Trial of ASK1 Inhibitor SRT-015 for NASH
6/23/2021
Seal Rock Therapeutics, Inc. today announced dosing of the first healthy volunteer in a Phase 1 clinical trial of SRT-015.